MedPath

Biodistribution and Dosimetry of 99mTc-Duramycin

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Registration Number
NCT05177640
Lead Sponsor
University Hospital, Antwerp
Brief Summary

Conduct a first-in-human study in healthy volunteers to show safety, biodistribution and dosimetry of \[99mTc\]Duramycin.

Detailed Description

Monocenter, prospective microdosing study in healthy volunteers. Healthy volunteers will undergo a \[99mTc\]Duramycin whole-body planar and abdominal SPECT scan at different time points after one iv injection of the radiotracer (1 h, 2h, 3h, 6h and 24h), while vital signs, urine and faces analysis will be checked. Blood samples will be taken at 12 different time points: 9 blood samples for dosimetry study and 3 blood samples will be subjected to clinical laboratory chemistry (renal and liver function chemistry, hematology, and blood coagulation parameters).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
6
Inclusion Criteria
  • Males (n=4) or females (n=4) age 18 years or older
  • Stated willingness to comply with all study procedures and availability for the duration of the study.
  • Ability to give study-specific written informed consent.
Exclusion Criteria
  • Pregnant or lactating females (positive pregnancy test)
  • Metal implants (e.g. pacemakers, osteosynthesis material)
  • Body weight > 100 kg
  • Severe claustrophobia
  • Abnormal kidney or liver function tests
  • Unable to comply with study requirements

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
99mTC-duramycin99mTc-Duramycinsingle dose of 99mTc-duramycin in healthy volunteers who will undergo SPECT-CT scanning at different time points
Primary Outcome Measures
NameTimeMethod
Determine the biodistribution of [99mTc]Duramycin.24 hours

Subjects will be dosed with 99mTc-Duramycin at Time 0 on Day 0, and a SPECT scan will be conducted immediately after the injection. Imaging will be repeated at 1 hour, 2 hours, 3 hours, 6 hours and 24 hours after dosing.

All images generated will be reviewed for biodistribution.

Determine the dosimetry evaluation of [99mTc]Duramycin.24 hours

Subjects will be dosed with 99mTc-Duramycin at Time 0 on Day 0, and a SPECT scan will be conducted immediately after the injection. Imaging will be repeated at 1 hour, 2 hours, 3 hours, 6 hours and 24 hours after dosing.

All images generated will be reviewed for dosimetry.

Secondary Outcome Measures
NameTimeMethod
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0"72 hours

Trial Locations

Locations (1)

University Hospital Antwerp

🇧🇪

Edegem, Antwerpen, Belgium

© Copyright 2025. All Rights Reserved by MedPath